Serologicals (NASDAQ:SERO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Serologicals Charts. Click Here for more Serologicals Charts.](/p.php?pid=staticchart&s=N%5ESERO&p=8&t=15)
Serologicals Corporation (NASDAQ: SERO) announced today
that Chemicon International, Inc., its wholly-owned subsidiary, and
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment,
TecDAX) have signed a three-year agreement for the distribution of
HuCAL(R)-based recombinant research antibodies through Chemicon's
worldwide sales network. MorphoSys's Antibodies by Design unit will
develop antibodies from its proprietary HuCAL GOLD(R) antibody library
against targets identified and supplied by Chemicon, a leading
provider of research tools. Chemicon may market the licensed
HuCAL(R)-based research antibodies for use in in vitro research as
stand-alone products or as components of reagent kits. In addition,
Chemicon may also market the antibodies for clinical diagnostic
applications. The parties are aiming to complete 100 research antibody
projects per year over the three year life time of the agreement.
MorphoSys receives payment for antibody generation, optional
additional fees, and royalties on all products. Further financial
details were not disclosed.
"The MorphoSys HuCAL(R) recombinant antibody technology will allow
us to rapidly generate the antibodies our customers are looking for,
and shorten our time to market in key target areas," commented Jeffrey
D. Linton, President of Chemicon. "We believe that the access to these
new antibodies will further strengthen our extremely broad portfolio
of antibody and immunological reagents within our targeted strategic
market segments."
"Joining forces with Chemicon as a leading provider of tools in
active research areas such as stem cell biology is a very attractive
opportunity for MorphoSys, and will provide the research community
with easy access to HuCAL(R) antibodies through Chemicon's strong
distribution network and market presence," commented Dr. Simon
Moroney, Chief Executive Officer of MorphoSys AG. "The contract
supports MorphoSys's goal to introduce a large number of HuCAL(R)
research antibodies into the market as quickly as possible, and will
continue to add to our revenues over the next couple of years through
an attractive royalty stream."
Chemicon International, Inc. offers a broad range of research
products, including specialty reagents, kits, antibodies, and custom
products and services, to customers working in the areas of
neuroscience, stem cell biology, cancer, and infectious disease
research. It is also a leading supplier of monoclonal antibodies,
conjugates, antibody blends and molecular-based detection kits for use
in diagnostic laboratories. Chemicon focuses on basic and biomedical
research, drug discovery, and diagnostics, allowing it to serve
thousands of customers worldwide in the academic, clinical,
biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon
is a Serologicals company, based in Temecula, CA.
For more information, please visit our website: www.chemicon.com.
Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta,
GA, is a global leader in developing and commercializing consumable
biological products, enabling technologies and services in support of
biological research, drug discovery, and the bioprocessing of
life-enhancing products. Our customers include researchers at major
life science companies and leading research institutions involved in
key disciplines, such as neurology, oncology, hematology, immunology,
cardiology, proteomics, infectious diseases, cell signaling and stem
cell research. In addition, Serologicals is the world's leading
provider of monoclonal antibodies for the blood typing industry.
Serologicals employs a total of more than 1,000 people worldwide in
three Serologicals' companies: Chemicon International, headquartered
in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville,
VA and Celliance Corporation, headquartered in Atlanta, GA.
For more information, please visit our website:
www.serologicals.com.
MorphoSys develops and applies innovative technologies for the
production of synthetic antibodies which accelerate drug discovery and
target characterization. Founded in 1992, the Company's proprietary
Human Combinatorial Antibody Library (HuCAL)(R) technology is used by
researchers worldwide for human antibody generation. The Company
currently has licensing agreements and/or research collaborations with
Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim,
Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc.
(Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany),
Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge,
Massachusetts/USA), Merck & Co., Inc. (New Jersey/USA), Novartis AG
(Basel, Switzerland), Novoplant GmbH (Gatersleben, Germany), Pfizer
Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering
AG (Berlin/Germany), Shionogi & Co., Ltd. (Japan), Xoma Ltd.
(Berkeley, California/USA) and others. Additionally, MorphoSys is
active in the antibody research market through its Antibodies by
Design business unit. Antibodies by Design was founded in 2003 for the
purpose of exploiting the MorphoSys non-therapeutic antibody markets.
MorphoSys' activities in the research antibody segment were
significantly strengthened through the acquisition of the U.K. and
U.S.-based Biogenesis Group in January 2005.
For further information please visit the corporate website at:
http://www.morphosys.com/.
This release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Words or phrases such as "should result," "are expected to," "we
anticipate," "we estimate," "we project" or similar expressions are
intended to identify forward-looking statements. These statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those expressed in any
forward-looking statements. You should not place undue reliance on
forward-looking statements, since the statements speak only as of the
date that they are made, and the Company undertakes no obligation to
update these statements based on events that may occur after the date
of this press release.
Serologicals is a registered trademark of Serologicals Royalty
Company.